NCT00215202 - Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

Nonresectable Adrenocortical Carcinoma

Interventions

DRUG

Iressa (ZD1839)

Trial Locations (4)

Kentuckiana Cancer Institute PLLC, Louisville

The University of Texas M.D. Anderson Cancer Center, Houston

Dana Farber Cancer Institute, Boston

Dartmouth-Hitchcock Medical Center, Lebanon